SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Sen. Bernie Sanders (I-Vt.) speaks during a pen and pad news conference on Capitol Hill on October 8, 2021. (Photo: Anna Moneymaker/Getty Images)
Sanders Calls on Biden to Slash 'Outrageous' Medicare Premium Hike
"It would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums" due to Big Pharma's greed, the Vermont senator said.
Dec 03, 2021
Sen. Bernie Sanders on Friday implored President Joe Biden to step in and prevent a looming Medicare premium hike stemming from the Food and Drug Administration's widely condemned approval of an expensive--and possibly ineffective--Alzheimer's drug.
In a letter to the president, Sanders (I-Vt.) noted that the pharmaceutical company Biogen has placed a $56,000-per-year price tag on Aduhelm, a treatment that the FDA approved in June despite experts' concerns about the dearth of evidence showing it actually works to slow Alzheimer's-induced cognitive decline.
"With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."
"Incredibly and immorally, Biogen... has set the price of this Alzheimer's drug at $56,000 even though the Institute for Clinical and Economic Review, an independent non-profit organization, has estimated that the maximum price of this drug should be no higher than $3,000-$8,400," the Vermont senator wrote. "This is a perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry."
Last month, as Common Dreams reported, the Centers for Medicare and Medicaid Services (CMS) announced that monthly Medicare Part B premiums would be increased to $170.10 in 2022, up from the current level of $148.50.
CMS officials attributed around half of the planned hike--which would be one of the largest in Medicare's history--to "additional contingency reserves due to the uncertainty regarding the potential use of the Alzheimer's drug, Aduhelm(tm), by people with Medicare."
Without the Aduhelm-related increase--which Sanders is pushing Biden to block--the monthly Medicare premium for 2022 would be around $159.
Medicare officials are still in the process of deciding whether the program will cover the exorbitantly priced drug, which the Department of Veterans Affairs decided not to include on its national formulary, citing "lack of evidence of a robust and meaningful clinical benefit."
Sanders called the planned premium increase "outrageous" and argued that "it would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums due to Biogen's greed and thirst for massive profits for a drug that has not been proven to be effective by the scientific community."
"The notion that one pharmaceutical company can raise the price of one drug so much that it could negatively impact 57 million senior citizens and the future of Medicare is beyond absurd," he continued. "With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."
Specifically, Sanders called on Biden to direct the U.S. Department of Health and Human Services to "immediately prevent the $11.50 a month increase in Medicare Part B premiums associated with Aduhelm from going into effect next year."
The senator also urged Biden to instruct CMS to delay its approval of Aduhelm and "take executive action to reinstate and expand the reasonable pricing clause that was established in 1989 by the National Institutes of Health requiring drug makers to charge reasonable prices for prescription drugs and treatments that receive federal funding."
Public health campaigners have been warning for months that the FDA's approval of Aduhelm--which led several agency advisers to resign in protest--could spell disaster for Medicare.
Dr. Michael Carome, director of Public Citizen's Health Research Group, said in a November statement that "all Part B Medicare beneficiaries soon will be forced to bear significant financial burden as a direct result of the FDA's reckless decision to approve [Aduhelm], a drug that has not been proven to provide any clinically meaningful benefit to Alzheimer's."
"To protect the many Medicare beneficiaries who cannot afford the unacceptable 15% jump in Part B premiums," Carome added, "CMS must promptly announce that it will exclude [Aduhelm] from coverage under the Medicare program until there is definitive evidence that the drug provides substantial... cognitive benefit to Alzheimer's disease patients."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Sen. Bernie Sanders on Friday implored President Joe Biden to step in and prevent a looming Medicare premium hike stemming from the Food and Drug Administration's widely condemned approval of an expensive--and possibly ineffective--Alzheimer's drug.
In a letter to the president, Sanders (I-Vt.) noted that the pharmaceutical company Biogen has placed a $56,000-per-year price tag on Aduhelm, a treatment that the FDA approved in June despite experts' concerns about the dearth of evidence showing it actually works to slow Alzheimer's-induced cognitive decline.
"With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."
"Incredibly and immorally, Biogen... has set the price of this Alzheimer's drug at $56,000 even though the Institute for Clinical and Economic Review, an independent non-profit organization, has estimated that the maximum price of this drug should be no higher than $3,000-$8,400," the Vermont senator wrote. "This is a perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry."
Last month, as Common Dreams reported, the Centers for Medicare and Medicaid Services (CMS) announced that monthly Medicare Part B premiums would be increased to $170.10 in 2022, up from the current level of $148.50.
CMS officials attributed around half of the planned hike--which would be one of the largest in Medicare's history--to "additional contingency reserves due to the uncertainty regarding the potential use of the Alzheimer's drug, Aduhelm(tm), by people with Medicare."
Without the Aduhelm-related increase--which Sanders is pushing Biden to block--the monthly Medicare premium for 2022 would be around $159.
Medicare officials are still in the process of deciding whether the program will cover the exorbitantly priced drug, which the Department of Veterans Affairs decided not to include on its national formulary, citing "lack of evidence of a robust and meaningful clinical benefit."
Sanders called the planned premium increase "outrageous" and argued that "it would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums due to Biogen's greed and thirst for massive profits for a drug that has not been proven to be effective by the scientific community."
"The notion that one pharmaceutical company can raise the price of one drug so much that it could negatively impact 57 million senior citizens and the future of Medicare is beyond absurd," he continued. "With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."
Specifically, Sanders called on Biden to direct the U.S. Department of Health and Human Services to "immediately prevent the $11.50 a month increase in Medicare Part B premiums associated with Aduhelm from going into effect next year."
The senator also urged Biden to instruct CMS to delay its approval of Aduhelm and "take executive action to reinstate and expand the reasonable pricing clause that was established in 1989 by the National Institutes of Health requiring drug makers to charge reasonable prices for prescription drugs and treatments that receive federal funding."
Public health campaigners have been warning for months that the FDA's approval of Aduhelm--which led several agency advisers to resign in protest--could spell disaster for Medicare.
Dr. Michael Carome, director of Public Citizen's Health Research Group, said in a November statement that "all Part B Medicare beneficiaries soon will be forced to bear significant financial burden as a direct result of the FDA's reckless decision to approve [Aduhelm], a drug that has not been proven to provide any clinically meaningful benefit to Alzheimer's."
"To protect the many Medicare beneficiaries who cannot afford the unacceptable 15% jump in Part B premiums," Carome added, "CMS must promptly announce that it will exclude [Aduhelm] from coverage under the Medicare program until there is definitive evidence that the drug provides substantial... cognitive benefit to Alzheimer's disease patients."
From Your Site Articles
Sen. Bernie Sanders on Friday implored President Joe Biden to step in and prevent a looming Medicare premium hike stemming from the Food and Drug Administration's widely condemned approval of an expensive--and possibly ineffective--Alzheimer's drug.
In a letter to the president, Sanders (I-Vt.) noted that the pharmaceutical company Biogen has placed a $56,000-per-year price tag on Aduhelm, a treatment that the FDA approved in June despite experts' concerns about the dearth of evidence showing it actually works to slow Alzheimer's-induced cognitive decline.
"With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."
"Incredibly and immorally, Biogen... has set the price of this Alzheimer's drug at $56,000 even though the Institute for Clinical and Economic Review, an independent non-profit organization, has estimated that the maximum price of this drug should be no higher than $3,000-$8,400," the Vermont senator wrote. "This is a perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry."
Last month, as Common Dreams reported, the Centers for Medicare and Medicaid Services (CMS) announced that monthly Medicare Part B premiums would be increased to $170.10 in 2022, up from the current level of $148.50.
CMS officials attributed around half of the planned hike--which would be one of the largest in Medicare's history--to "additional contingency reserves due to the uncertainty regarding the potential use of the Alzheimer's drug, Aduhelm(tm), by people with Medicare."
Without the Aduhelm-related increase--which Sanders is pushing Biden to block--the monthly Medicare premium for 2022 would be around $159.
Medicare officials are still in the process of deciding whether the program will cover the exorbitantly priced drug, which the Department of Veterans Affairs decided not to include on its national formulary, citing "lack of evidence of a robust and meaningful clinical benefit."
Sanders called the planned premium increase "outrageous" and argued that "it would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums due to Biogen's greed and thirst for massive profits for a drug that has not been proven to be effective by the scientific community."
"The notion that one pharmaceutical company can raise the price of one drug so much that it could negatively impact 57 million senior citizens and the future of Medicare is beyond absurd," he continued. "With Democrats in control of the White House, the House, and the Senate, we cannot let that happen."
Specifically, Sanders called on Biden to direct the U.S. Department of Health and Human Services to "immediately prevent the $11.50 a month increase in Medicare Part B premiums associated with Aduhelm from going into effect next year."
The senator also urged Biden to instruct CMS to delay its approval of Aduhelm and "take executive action to reinstate and expand the reasonable pricing clause that was established in 1989 by the National Institutes of Health requiring drug makers to charge reasonable prices for prescription drugs and treatments that receive federal funding."
Public health campaigners have been warning for months that the FDA's approval of Aduhelm--which led several agency advisers to resign in protest--could spell disaster for Medicare.
Dr. Michael Carome, director of Public Citizen's Health Research Group, said in a November statement that "all Part B Medicare beneficiaries soon will be forced to bear significant financial burden as a direct result of the FDA's reckless decision to approve [Aduhelm], a drug that has not been proven to provide any clinically meaningful benefit to Alzheimer's."
"To protect the many Medicare beneficiaries who cannot afford the unacceptable 15% jump in Part B premiums," Carome added, "CMS must promptly announce that it will exclude [Aduhelm] from coverage under the Medicare program until there is definitive evidence that the drug provides substantial... cognitive benefit to Alzheimer's disease patients."
From Your Site Articles
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.